Jazz Pharmaceuticals Announces US FDA Approval of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults - PRNewswire

Submitted by Anonymous (not verified) on Thu, 08/12/2021 - 18:30

Jazz Pharmaceuticals Announces US FDA Approval of Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia in Adults PRNewswire

Log in to post comments